Asthma is one of the commonest chronic illnesses of childhood. Current data suggests global prevalence of 1-18 % in different populations with a consistent rise in asthma burden [1, 2] . Also, acute exacerbation of asthma is a common reason for emergency room visits translating to tremendous economic costs. To combat it numerous researches have been directed towards finding the most appropriate methods of asthma control.
Whereas inhaled short acting beta 2 agonists (SABA) remain the mainstay for control of an acute exacerbation, systemic corticosteroids are warranted in moderate to severe exacerbations and in those who show poor response to initial SABA therapy [3] . However, there is significant heterogeneity in response to the major classes of asthma medications. Up to 50 % of variability in therapeutic response has been attributed to inter individual genetic differences [4] . Pharmacogenetics evaluates the effects of these genetic variations on drug response, safety and tolerability and heralds personalized medicine in diseases like asthma.
Genes involved in the pharmacokinetics and pharmacodynamics of various asthma medications have been studied to identify loci that contribute to heterogeneity in response. Candidate gene study approaches, genotype stratified study designs and genome wide association studies of the glucocorticoid, leukotriene, and β 2 -adrenergic receptor (ADRB2) pathways have identified about 13 genetic loci of ADRB2 agonists, 8 gene loci in leukotriene genes and seven for inhaled corticosteroids associated with modified therapeutic responsiveness in asthma [5] . Of these, the ADRB2 gene polymorphisms for beta agonist response and ALOX5 in leukotriene pathway have been the most studied pharmacogenetic targets. Likewise multiple genes involved in the corticosteroid pathway have been studied including the CRHR1, TBX21, FCER2 and AC9 gene variations [6] . A recent metanalysis showed polymorphisms in a novel susceptibility ST13 gene to be associated with asthma exacerbation despite use of inhaled corticosteroids [7] . Another gene, the CRHR1 (Corticotrophin Releasing Hormone Receptor 1) gene is found to influence steroid response in asthmatics [8] . Certain single nucleotide polymorphisms (SNPs) {rs242939 (A > G) and rs242941 (G > T)} in CRHR1 gene are associated with significant improvement in lung function in response to inhaled corticosteroids [8] . The proposed mechanism is that specific CRHR1 gene mutations are associated with lower basal levels of endogenous steroids, thus providing an opportunity of enhanced action by exogenously administered steroids.
The study by Awasthi et al. published in this edition of the journal also focuses on these two SNPs in CRHR1 gene [9] . The homozygotes or heterozygotes for the mutant allele of CRHR1 gene SNP rs242941 showed better response to systemic steroids than those with homozygous wild genotype. However, genetic variants of SNP rs242939 did not show any relation to steroid response [9] . Previous studies have shown discordant results. Tantisara et al. demonstrated significant improvement in lung function in children with mutant allele of SNP rs242941 [8] . However, research by Rogers et al. revealed completely contrasting results with poor lung function in those with mutant allele [10] . Dijkstra et al. refuted any association between SNPs of CRHR1 and response to steroids [11] . Also, the SNPs in question (rs242941 and rs242939) are actually present in the non coding region of CRHR1 gene and thus are unlikely to affect the function of CRHR1 by themselves. However, by virtue of linkage disequilibrium, these SNPs are related to particular haplotypes of CRHR1 gene which contain the actual causal variant. Since the SNPs are indirect markers of the actual causal variant, the reproducibility of results in different populations is likely to be affected [8] . Thus, the relation between SNPs of CRHR1 gene and corticosteroid responsiveness is still not defined. The novelty of the study by Awasthi et al. lies in the fact that it is the first study to assess the response to 'systemic' steroids in acute asthma exacerbation whereas all previous studies have focussed on 'long term' response to 'inhaled' steroids. Since, systemic steroids form an important management tool in treatment of acute asthma exacerbation, it will be beneficial to know the population likely to show good response and those who are at an increased risk of adverse effects. However, lack of adequately reproducible results limits the use of these polymorphisms to predict therapeutic response to steroids.
There are many challenges in conducting pharmacogenetic studies in complex diseases like asthma where several genetic and environmental factors are likely to influence the multiple interacting biological pathways. Firstly, the biological pathway for corticosteroid action is complex and controlled by several genes. It is unlikely that a polymorphism of a single gene by itself would produce significant changes in that pathway. However, a combination of polymorphisms of multiple genes may alter steroid action. For example, the CRHR1 gene polymorphisms alone account for less than 3 % variability in response to steroids [6] . Secondly, gene-gene interactions may modify the observed effects. For instance, favourable polymorphisms of ADRB2 and unfavourable polymorphisms of CRHR1 may co-exist and confound the clinically observed effects. Importantly, a note should be made of the ethnic background of the studied population. A certain gene variation may occur at a higher frequency in a particular racial group compared to others. Similarly, a polymorphism with a favourable prognosis in a particular ethnic group may show completely contradictory results in a different population. This is of particular relevance to the Indian population where the diverse ethnicity makes extrapolation of results difficult. In addition, lack of uniformity in definition and assessment of response has led to difficulty in interpretation and comparability of results in different studies [10] . In the current study [9] , though GINA guidelines have been used for definition of response, the assessment is subjective and clinician based. Use of objective parameters like FEV1 would have made comparison with previous studies easier. Moreover, larger sample sizes are needed to get statistically significant results.
Finally, it would be prudent to say that a careful search on the utility of pharmacogenomic predictions should be done.
Greater frequency of the mutant allele and stronger association with drug effect would make the test more economical and therapeutically applicable. Assessment of multiple genetic variations in carefully selected cohorts of asthmatic children, carried on a large scale and in diverse ethnic groups is needed. This would help develop a pharmacogenetic profile panel that would not only be predictive of the optimal initial course of asthma treatment but would also predict the other adjunctive therapeutic options, providing tailored therapy for an individual.
